Amphastar Pharmaceuticals, Inc. Retained Earnings
Amphastar Pharmaceuticals, Inc. (AMPH) had Retained Earnings of $703.65 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) $703.65M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) $673.30M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) $666.88M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) $642.45M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | $703.65M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $673.30M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $666.88M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $642.45M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $625.10M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $594.07M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $568.79M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $530.82M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $490.39M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $452.44M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $409.27M 10-K · filed 2025-03-03 | |
| 2023-09-30 | $373.10M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $323.88M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $297.75M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $271.72M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $237.81M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $221.94M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $204.59M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $180.34M 10-K · filed 2023-03-01 | |
| 2021-09-30 | $160.58M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $130.58M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $122.81M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $117.77M 10-K · filed 2022-03-11 | |
| 2020-09-30 | $124.05M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $120.13M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $120.32M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $116.37M 10-K · filed 2021-03-15 | |
| 2019-09-30 | $117.40M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $116.09M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $68.30M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $67.48M 10-K · filed 2020-03-16 | |
| 2018-09-30 | $65.62M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $66.78M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $69.57M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $72.64M 10-K · filed 2019-03-15 | $76.23M 10-K · filed 2018-03-14 |
| 2017-09-30 | $74.77M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $74.59M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $72.62M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $70.86M 10-K · filed 2018-03-14 | |
| 2016-09-30 | $73.60M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $69.71M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $62.81M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $60.32M 10-K · filed 2017-03-15 | |
| 2015-09-30 | $52.79M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $55.80M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | $62.45M 10-Q · filed 2015-05-14 | |
| 2014-12-31 | $63.11M 10-K · filed 2016-03-15 | |
| 2014-09-30 | $65.63M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $71.01M 10-Q · filed 2014-08-13 | |
| 2013-12-31 | $73.81M 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |